V-160 is a Vaccine owned by Merck & Co, and is involved in 3 clinical trials, which were completed.
V-160 works by provoking body's immune response against the virus, without causing the disease. The vaccine stimulates the immunological agents including the antibodies against the Cytomegalo virus. These immunological agents help the body recognize and kill the foreign organisms. These antibodies thus protect the body against future infections with the same organisms.
The revenue for V-160 is expected to reach a total of $611m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the V-160 NPV Report.
V-160 is originated and owned by Merck & Co.
V-160 is under development for the prevention of Cytomegalovirus infections. The vaccine candidate is administered as an intramuscular and intradermal injection.
Merck & Co Overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.
Quick View – V-160
|Highest Development Stage|